Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by Axa S.A.

Axa S.A. grew its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 11.4% in the second quarter, according to its most recent filing with the SEC. The firm owned 34,018 shares of the company’s stock after acquiring an additional 3,479 shares during the quarter. Axa S.A. owned about 0.11% of Medpace worth $14,010,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of MEDP. Rise Advisors LLC acquired a new stake in Medpace in the first quarter worth about $27,000. Mather Group LLC. bought a new stake in shares of Medpace during the 1st quarter worth about $28,000. Fidelis Capital Partners LLC bought a new stake in shares of Medpace during the 1st quarter worth about $31,000. J.Safra Asset Management Corp lifted its stake in shares of Medpace by 87.0% in the 1st quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock worth $41,000 after acquiring an additional 47 shares during the period. Finally, DT Investment Partners LLC bought a new position in shares of Medpace in the second quarter valued at approximately $41,000. Institutional investors own 77.98% of the company’s stock.

Medpace Trading Up 1.6 %

NASDAQ MEDP opened at $331.44 on Friday. Medpace Holdings, Inc. has a 1 year low of $227.21 and a 1 year high of $459.77. The company has a market cap of $10.27 billion, a PE ratio of 33.79, a PEG ratio of 1.88 and a beta of 1.35. The stock’s 50-day moving average price is $370.19 and its two-hundred day moving average price is $390.19.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, July 22nd. The company reported $2.75 EPS for the quarter, beating the consensus estimate of $2.54 by $0.21. Medpace had a net margin of 16.74% and a return on equity of 55.14%. The business had revenue of $528.10 million during the quarter, compared to the consensus estimate of $528.41 million. During the same quarter in the prior year, the firm earned $1.93 EPS. The firm’s quarterly revenue was up 14.6% on a year-over-year basis. Research analysts forecast that Medpace Holdings, Inc. will post 11.66 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on MEDP. Truist Financial started coverage on Medpace in a report on Thursday, August 1st. They set a “hold” rating and a $415.00 target price on the stock. Guggenheim cut their price objective on Medpace from $464.00 to $432.00 and set a “buy” rating for the company in a report on Wednesday, July 24th. Deutsche Bank Aktiengesellschaft decreased their target price on Medpace from $395.00 to $336.00 and set a “hold” rating for the company in a research note on Wednesday, July 24th. StockNews.com cut shares of Medpace from a “buy” rating to a “hold” rating in a research report on Friday. Finally, Robert W. Baird reduced their price objective on shares of Medpace from $430.00 to $413.00 and set an “outperform” rating for the company in a research report on Friday, September 20th. Five research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Medpace currently has a consensus rating of “Moderate Buy” and an average target price of $395.00.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.